Current Period Performance Forecast The company forecasts a substantial increase in net profit attributable to shareholders for H1 2025, driven by non-operating income, despite a significant decline in core business profitability Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Profit: 100 million - 135 million Yuan | Profit: 29.59 million Yuan | | Year-over-Year Change | Increase 237.95% - 356.24% | - | | Net Profit Excluding Non-Recurring Gains and Losses | Profit: 19 million - 35 million Yuan | Profit: 120.51 million Yuan | | Year-over-Year Change | Decrease 70.96% - 84.23% | - | | Basic Earnings Per Share | Profit: 0.10 Yuan/Share – 0.13 Yuan/Share | Profit: 0.03 Yuan/Share | | Basic EPS Excluding Non-Recurring Items | Profit: 0.02 Yuan/Share - 0.03 Yuan/Share | Profit: 0.12 Yuan/Share | Communication with Accounting Firm The company has conducted preliminary discussions with its annual audit firm regarding the performance forecast, with no significant disagreements, though the forecast remains unaudited by a certified public accountant - This performance forecast has not been pre-audited by a certified public accountant, but the company has conducted preliminary discussions with its annual audit firm on related matters, with no significant disagreements3 Explanation of Performance Changes Performance changes during the reporting period show a divergence: significant growth in net profit attributable to shareholders is primarily due to a positive impact from fair value changes of financial assets, while a sharp decline in non-recurring net profit stems from continuous price reductions of core products affecting revenue and profitability - Net profit attributable to shareholders significantly increased year-over-year, primarily due to non-recurring gains and losses, specifically fair value changes of financial assets, with a gain of approximately 110 million yuan in H1 2025 compared to a loss of 118 million yuan in the prior period, representing a 228 million yuan increase4 - Net profit excluding non-recurring items significantly decreased year-over-year, primarily due to continuous price reductions of the company's main products during the reporting period, leading to lower operating revenue and profit4 Risk Warning The company explicitly states that this performance forecast is a preliminary estimate by the finance department, with final accurate financial data subject to the 2025 semi-annual report, advising investors to exercise caution and be aware of investment risks - This performance forecast represents preliminary estimates by the company's finance department, with specific financial data to be fully disclosed in the company's 2025 semi-annual report5 - Investors are advised to exercise caution in their decisions and be mindful of investment risks5
双鹭药业(002038) - 2025 Q2 - 季度业绩预告